Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-07-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the Hong Kong Stock Exchange regarding the Company entering into an exclusive license agreement for its drug candidate with Madrigal. It is not an earnings release, board/management change notice, dividend announcement, M&A takeover bid, or any of the other specific categories such as interim report or proxy materials. Instead, it is a standalone regulatory announcement of a corporate licensing transaction. It therefore falls under the fallback category for general regulatory announcements (RNS).
2025-07-30 English
NEXT DAY DISCLOSURE RETURNS
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares and treasury shares, including new issues under share schemes and share awards. It reports specific share issuance events, closing balances, and confirmations under Listing Rules. This corresponds to an announcement of capital changes (new share issues), fitting the “Share Issue/Capital Change” category.
2025-07-21 English
VOLUNTARY ANNOUNCEMENT - MESALAZINE ENTERIC-COATED TABLETS OBTAIN DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of Mesalazine Enteric-Coated Tablets by the National Medical Products Administration of China. It does not present financial results (ER, IR), Board or Management changes (MANG), capital transactions (CAP, SHA, POS), regulatory stress tests or audits (AR), nor is it a proxy, dividend, or vote result announcement. It is not a report publication notice but a standalone regulatory announcement about product approval. This fits the fallback category for miscellaneous regulatory announcements (RNS).
2025-07-04 English
VOLUNTARY ANNOUNCEMENT - HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA (MMA)
Regulatory Filings Classification · 1% confidence The document is a voluntary regulatory announcement by CSPC Pharmaceutical published on the Hong Kong Exchange website, informing investors that their high-concentration hydroxocobalamin hydrochloride injection has obtained clinical trial approval in China. There is no financial data, no AGM materials, no earnings metrics, no board changes, no dividend information, and no request for shareholder votes. It does not represent a full report (10-K, IR, etc.) but is a standalone regulatory update about product approval. This falls into the general “Regulatory Filings” category for miscellaneous regulatory announcements (RNS).
2025-07-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025
Share Issue/Capital Change Classification · 1% confidence The document is a statutory monthly return (Form FF301) filed to the Hong Kong Exchange detailing movements in issued shares, treasury shares, and share options for the month ended 30 June 2025. It reports increases in issued share capital due to option exercises. This falls under announcements of share issues and capital changes rather than an annual report, earnings release, or board/management update. Therefore, it best matches the “Share Issue/Capital Change” category (SHA).
2025-07-03 English
NOMINATION COMMITTEE - TERMS OF REFERENCE
Governance Information Classification · 1% confidence The document is the amended Terms of Reference for the Nomination Committee, detailing its composition, responsibilities, reporting lines, and authority. It is an internal governance charter outlining board structure and committee procedures rather than a financial report, earnings release, or announcement. Therefore, it falls under Governance Information (CGR).
2025-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.